Please wait a minute...
1Traditional Medicine Research  2020, Vol. 5 Issue (3): 160-166    DOI: 10.12032/TMR20200406172
Special Issue on Infectious Diseases and Public Health     
The potential application of the traditional Chinese herb Exocarpium Citri grandis in the prevention and treatment of COVID-19
Wei-Wei Su1,*(), Yong-Gang Wang1, Pei-Bo Li1, Hao Wu1, Xuan Zeng1, Rui Shi1, Yu-Ying Zheng1, Pan-Lin Li1, Wei Peng1
1Guangdong Engineering & Technology Research Center for Quality and Efficacy Reevaluation of Post-Market Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
Download: HTML     PDF(452KB)
Export: BibTeX | EndNote (RIS)      

Highlights

In this review, the researchers summarized the characteristics and associated mechanisms of naringin, the pharmacologically active compound of the Chinese herb Huajuhong (Exocarpium Citri grandis, ECG) in alleviating multiple respiratory diseases, and discussed its potential application in the prevention and treatment of coronavirus disease 2019.

Traditionality

The Chinese herb Huajuhong is the dried epicarp of ECG, an herb that originated from Huazhou town in the Guangdong province of South China. It was first documented in an ancient book of traditional Chinese medicine, Bencao Gangmu Shiyi (Supplement to Compendium of Materia Medica), which was written in 1765 C.E. It has been used as folk herbal medicine in the treatment of respiratory diseases for hundreds of years in China. ECG was included in the Chinese Pharmacopoeia since 1977 and was a primary ingredient in many famous traditional Chinese medicine prescriptions. ECG contains flavonoids, and naringin is the primary active component[9].

Abstract

Huajuhong (Exocarpium Citri grandis, ECG) is a traditional Chinese herbal medicine and has been used for the treatment of respiratory diseases for hundreds of years. Recently, ECG has been listed in a traditional Chinese medicine formula in the Guidelines for the Diagnosis and Treatment of Coronavirus Disease 2019 (sixth edition) in China. To date, the effect and mechanism of ECG against respiratory diseases have not been systematically reviewed. In this paper, the researchers summarized the effects of ECG and its pharmacologically active compound naringin in functioning as an antitussive and expectorant, improving lung function, alleviating acute lung injury, attenuating pulmonary fibrosis, and enhancing antiviral immune response, so as to provide a reference for its clinical application in the prevention and treatment of multiple respiratory diseases, including coronavirus disease 2019.



Key wordsHuajuhong      Exocarpium Citri grandis      Naringin      coronavirus disease 2019      Clinical application     
Published: 13 April 2020
Fund:  This work was supported by Science and Technology Planning Project of Guangdong Province in China (2018A030313491, 2019B090905002).
Corresponding Authors: Wei-Wei Su   
E-mail: lsssww@126.com
Cite this article:

Wei-Wei Su, Yong-Gang Wang, Pei-Bo Li, Hao Wu, Xuan Zeng, Rui Shi, Yu-Ying Zheng, Pan-Lin Li, Wei Peng. The potential application of the traditional Chinese herb Exocarpium Citri grandis in the prevention and treatment of COVID-19. 1Traditional Medicine Research, 2020, 5(3): 160-166. doi: 10.12032/TMR20200406172

URL:

https://www.tmrjournals.com/tmr/EN/10.12032/TMR20200406172

Figure 1 The therapeutic effects of Exocarpium Citri grandis against multiple respiratory diseases.
1.   Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020, 76: 71-76.
2.   Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020, 20: 124-127.
3.   Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.
4.   Jiang F, Deng L, Zhang L, et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020: 1-5.
5.   Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020: 1-6.
6.   Dai WC, Zhang HW, Yu J, et al. CT imaging and differential diagnosis of COVID-19. Can Assoc Radiol J 2020, 71: 195-200.
7.   Liu Q, Wang R, Qu G, et al. General anatomy report of novel coronavirus pneumonia death corpse. J Forensic Med 2020, 36: 19-21.
8.   Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020, 55: 105924.
9.   Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020, 155: 104743.
10.   Li P, Liu M, Hu J, et al. Systematic chemical profiling of Citrus grandis ‘Tomentosa’ by ultra-fast liquid chromatography/diode-array detector/quadrupole time-of-flight tandem mass spectrometry. J Pharm Biomed Anal 2014, 90: 167-179.
11.   Jiang K, Song Q, Wang L, et al. Antitussive, expectorant and anti-inflammatory activities of different extracts from Exocarpium Citri grandis. J Ethnopharmacol 2014, 156: 97-101.
12.   Yuan YP, Zhai HQ, Guo ZJ, et al. Analysis of historical origin and standardization system construction of Citri Grandis Exocarpium. Chin J Chin Mater Med 2017, 42: 2214-2218.
13.   Committee for the Pharmacopoeia of Peopl’s Republic of China. Pharmacopoeia of People’s Republic of China, Part 1. Beijing: Chemical Industry Publishing House, 2015.
14.   Li P, Ma Y, Wang Y, et al. Experimental studies on antitussive,expectorant and antiasthmatic effects of extract from Citrus grandis var. tomentosa. Chin J Chin Mater Med 2006, 31: 1350-1352.
15.   Zhu Z, Wu H, Su W, et al. Effects of total flavonoids from Exocarpium Citri Grandis on air pollution particle-induced pulmonary inflammation and oxidative stress in mice. J Food Sci 2019, 84: 3843-3849.
16.   Li P, Ma Y, Yang H, et al. Anti-inflammatory effects of Exocarpium Citri grandis extract. Chin Tradit Herb Drug 2006, 37: 251-253. (Chinese)
17.   Li P, Su C, Bi F, et al. Study on antitussive effect and mechanism of Exocarpium Citri grandis extract. Chin Tradit Herb Drug 2008, 38: 247-250. (Chinese)
18.   Li P, Wang Y, Peng W, et al. Safety pharmacological study of the effects of Exocarpium Citri grandis extract on central nervous system in mice. Journal of Chinese Medicinal Materials 2007, 30: 1438-1438. (Chinese)
19.   Zeng X, Su W, Zheng Y, et al. UFLC-Q-TOF-MS/MS-based screening and identification of flavonoids and derived metabolites in human urine after oral administration of Exocarpium Citri Grandis extract. Molecules 2018, 23: 895.
20.   Yao H, Su W, Lin L, et al. Comprehensive investigation into the interconversion of C-2 diastereomers of naringin. Chirality 2018, 30: 652-660.
21.   Bharti S, Rani N, Krishnamurthy B, et al. Preclinical evidence for the pharmacological actions of naringin: a review. Planta Med 2014, 80: 437-451.
22.   Patel K, Singh GK, Patel DK. A review on pharmacological and analytical aspects of naringenin. Chin J Integr Med 2018, 24: 551-560.
23.   Salehi B, Fokou PVT, Sharifi-Rad M, et al. The therapeutic potential of naringenin: a review of clinical trials. Pharmaceuticals (Basel). 2019, 12: 11.
24.   Li P, Wang Y, Wu Z, et al. The pre-clinical studies of naringin, an innovative drug, derived from Citri Grandis Exocarpium (Huajuhong). Acta Sci Nat Univ Sunyatseni 2015, 54: 1-5.
25.   Zeng X, Su W, Liu B, et al. A review on the pharmacokinetic properties of naringin and its therapeutic efficacies in respiratory diseases. Mini Rev Med Chem 2019, 22: 286-293.
26.   Gao S, Li P, Yang H, et al. Antitussive effect of naringin on experimentally induced cough in Guinea pigs. Plant Med 2011, 77: 16-21.
27.   Lin B, Li P, Wang Y, et al. The expectorant activity of naringenin. Pulm Pharmacol Ther 2008, 21: 259-263.
28.   Nie YC, Wu H, Li PB, et al. Anti-inflammatory effects of naringin in chronic pulmonary neutrophilic inflammation in cigarette smoke-exposed rats. J Med Food 2012, 15: 894-900.
29.   Su W, Wang Y, Fang T, et al. Application of naringin in preparation of supportive treatment for SARS. China patent ZL03126908.7. 2004. (Chinese)
30.   National Health Commission of the People’s Republic of China. Diagnosis and Treatment Protocol for COVID-19 (trial version 6). Beijing, 2020. (Chinese)
31.   Luo YL, Zhang CC, Li PB, et al. Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke. Inter Immunopharmacol 2012, 13: 301-307.
32.   Jiao H, Su W, Li P, et al. Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma. Pulm Pharmacol Ther 2015, 33: 59-65.
33.   Widdicombe J. Neuroregulation of cough: implications for drug therapy. Curr Opin Pharmacol 2002, 2: 256-263.
34.   Shi R, Xu JW, Xiao ZT, et al. Naringin and naringenin relax rat tracheal smooth by regulating BKCa activation. J Med Food 2019, 22: 963-970.
35.   Nie Y, Wu H, Li P, et al. Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IκB-NF-κB signaling pathways. Eur J Pharmacol 2012, 690: 207-213.
36.   Shi R, Xiao ZT, Zheng YJ, et al. Naringenin regulates CFTR activation and expression in airway epithelial cells. Cell Physiol Biochem 2017, 44: 1146-1160.
37.   Shi R, Su WW, Zhu ZT, et al. Regulation effects of naringin on diesel particulate matter-induced abnormal airway surface liquid secretion. Phytomed 2019, 63: 153004.
38.   Liu Y, Wu H, Nie Y, et al. Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway. Inter Immunopharmacol 2011, 11: 1606-1612.
39.   Chen Y, Wu H, Nie Y, et al. Mucoactive effects of naringin in lipopolysaccharide-induced acute lung injury mice and beagle dogs. Environ Toxicol Pharmacol 2014, 38: 279-287.
40.   Peng Y, Hu M, Lu Q, et al. Flavonoids derived from Exocarpium Citri Grandis inhibit LPS-induced inflammatory response via suppressing MAPK and NF-κB signalling pathways. Food Agric Immunol 2019, 30: 564-580.
41.   Li P, Liao Y, Liu H, et al. Naringin’s influence on the protein expressions in the lung tissues of cigarette smoke induced acute lung inflammation in mice by iTRAQ technology. Acta Sci Nat Univ Sunyatseni 2017, 56: 102-110.
42.   Meyer KC. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med 2017, 11: 343-359.
43.   Chen Y, Nie Y, Luo Y, et al. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. Food Chem Toxicol 2013, 58: 133-140.
44.   Cheng L, Zheng W, Li M, et al. Citrus fruits are rich in flavonoids for immunoregulation and potential targeting ACE2. Preprints 2020.
45.   Zeng X, Bai Y, Peng W, et al. Identification of naringin metabolites in human urine and feces. Eur J Drug Metab Pharmacokinet 2017, 42: 647-656.
46.   Zou W, Luo Y, Liu M, et al. Human intestinal microbial metabolism of naringin. Eur J Drug Metab Pharmacokinet 2015, 40: 363-367.
47.   Chen T, Su W, Yan Z, et al. Identification of naringin metabolites mediated by human intestinal microbes with stable isotope-labeling method and UFLC-Q-TOF-MS/MS. J Pharm Biomed Anal 2018, 161: 262-272.
48.   Zeng X, Yao H, Zheng Y, et al. Tissue distribution of naringin and derived metabolites in rats after a single oral administration. J Chromatogr B 2020, 1136: 121846.
49.   Steed AL, Christophi GP, Kaiko GE, et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 2017, 357: 498-502.
50.   Chen T, Wu H, He Y, et al. Simultaneously quantitative analysis of naringin and its major human gut microbial metabolites naringenin and 3-(4'-hydroxyphenyl) propanoic acid via stable isotope deuterium-labeling coupled with RRLC-MS/MS method. Molecules 2019, 24: 4287.
51.   Zeng X, Yao H, Zheng Y, et al. Metabolite profiling of naringin in rat urine and feces using stable isotope-labeling-based liquid chromatography-mass spectrometry. J Agric Food Chem 2020, 68: 409-417.
[1] Lu Yang, Ning Li, Hai-Bo Hu, Bin Yin, Guo-Jing Zhao, Feng-Chan Wang, Xu-Hui Wang, Hong-Wu Wang, Xue-Chao Lu, Huan-Tian Cui. Can Yin-Chai-Xiao-Du decoction be useful of COVID-19? the mechanism research based on network pharmacology[J]. 1Traditional Medicine Research, 2020, 5(4): 188-200.
[2] Yu-Xuan Zhang, Ying Quan, Ming-Hu Chen, Duo Zhang, Ying Zhang, Zhen-Gang Zhu. Does Liuzijue Qigong affect anxiety in patients with chronic obstructive pulmonary disease, even during the COVID-19 outbreak? a randomized, controlled trial[J]. 1Traditional Medicine Research, 2020, 5(4): 216-228.
[3] Lu Yang, Yu-Ting Li, Jing Miao, Li Wang, Hui Fu, Qin Li, Wei-Bo Wen, Zhai-Yi Zhang, Rui-Wen Song, Xiang-Guo Liu, Hong-Wu Wang, Huan-Tian Cui. Network pharmacology studies on the effect of Chai-Ling decoction in coronavirus disease 2019[J]. 1Traditional Medicine Research, 2020, 5(3): 145-159.
[4] Huan-Tian Cui, Yu-Ting Li, Li-Ying Guo, Xiang-Guo Liu, Lu-Shan Wang, Jian-Wei Jia, Jia-Bao Liao, Jing Miao, Zhai-Yi Zhang, Li Wang, Hong-Wu Wang, Wei-Bo Wen. Traditional Chinese medicine for treatment of coronavirus disease 2019: a review[J]. 1Traditional Medicine Research, 2020, 5(2): 65-73.
[5] Liu Lin, Zhao Zhi-Gang. The present treatment and mechanism progress of arsenic trioxide in hematological malignancies[J]. 1Traditional Medicine Research, 2016, 1(3): 115-121.